Adagio |

Our mission is to provide an effective long-term solution for the global coronavirus challenge.

Highly potent broadly neutralizing antibodies offer the best possibility to resolve the current COVID19 pandemic while also preparing for future outbreaks of related viruses.

Our best-in-class broadly neutralizing antibodies can meet the current and future challenges posed by the spillover of coronaviruses into humans.

Our mission is to provide an effective long-term solution for the global coronavirus challenge.

Highly potent broadly neutralizing antibodies offer the best possibility to squelch the current COVID19 pandemic while also preparing for future outbreaks of related viruses.

Our best in class broadly neutralizing antibodies can meet the current and future challenges posed by the spillover of coronaviruses into humans.

About Us

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic by the end of 2020.

Management Team

Tillman Gerngross, Ph.D.

Co-Founder & CEO

Halley Gilbert

Chief Operating Officer

Laura Walker, Ph.D.

Co-Founder & Chief Scientific Officer

Ellie Hershberger, PharmD

Chief Development Officer

Becky Dabora, Ph.D.

Chief Technology & Manufacturing Officer

Lynn Connolly, MD, Ph.D.

Chief Medical Officer

Eric Kimble, M.B.A.

Chief Commercial Officer

Jane Pritchett Henderson

Chief Financial Officer

MEDIA & PUBLICATIONS

Science

PRESS RELEASES

– – – – – – –

07.19.21

Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer

– – – – – – –

05.05.21

Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

– – – – – – –

04.19.21

Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19

– – – – – – –

04.13.21

Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19

– – – – – – –

02.22.21

Adagio Therapeutics to Participate in Cowen 41st Annual Health Care Conference

– – – – – – –

02.16.21

Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19

– – – – – – –

01.25.21

Adagio Therapeutics Publishes Preclinical Data in Science Demonstrating Best-in-Class Breadth and Potency Against SARS-CoV-2, Including Known Circulating Resistance Variants, and a Range of Pre-Emergent Coronaviruses

– – – – – – –

11.18.20

Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat

– – – – – – –

11.10.2020

Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention

– – – – – – –

9.09.2020

Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical Operations

– – – – – – –

8.24.2020

Adagio Therapeutics Announces Appointment of Howard Mayer, M.D., to its Board of Directors

– – – – – – –

7.16.2020

Adagio Therapeutics Launches with $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and Prophylaxis

– – – – – – –

PUBLICATIONS

Relevant Publications by
Adagio Scientists:

– – – – – – –

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Nature Medicine

– – – – – – –

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Science Immunology

– – – – – – –

Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections

MDPI

– – – – – – –

Rational Vaccine Design in the Time of COVID-19

Cell Host Microbe

– – – – – – –

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Science

– – – – – – –

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

BioRxiv

– – – – – – –

Wec AZ et al. Broad neutralization of SARS-related antibodies by human monoclonal antibodies. Science. 2020 Jun 15.

Science

– – – – – – –

Wec AZ et al. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685.

Proceedings of the National Academy of Sciences (PNAS)

– – – – – – –

Shehata L et al. Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments. Nat Commun. 2019 Mar 8; 10(1):1126.

Nature Communications

– – – – – – –

West BR et al. Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nat Struct Mol Biol. 2019 Mar; 26(3):204-212.

Nature Structural and Molecular Biology

– – – – – – –

Bornholdt ZA et al. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host Microbe. 2019 Jan 9; 25(1):49-58.e5.

Cell Host and Microbe

– – – – – – –

Wec AZ et al. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host Microbe. 2019 Jan 9; 25(1):39-48.e5.

Cell Host and Microbe

– – – – – – –

Saphire EO et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection (2018). Cell. Aug 09; 174(4):938-952.

Cell

– – – – – – –

Goodwin E et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation (2018). Immunity. Feb 20; 48(2):339-349

Immunity

– – – – – – –

Walker LM et al. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray (2018). Nat Rev Immunol. May; 18(5):297-308.

Nature Reviews Immunology

– – – – – – –

Rogers TF et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors (2017). Sci Immunol. Aug 18; 2(14).

Science Immunology

– – – – – – –

Wec AZ et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses (2017). Cell. May 18; 169(5):878-890.

Cell

– – – – – – –

Gilman MS et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors (2016). Sci Immunol. Dec 16; 1(6).

Science Immunology

– – – – – – –

Badarau A et al. Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies (2016). MAbs. Jul 28:0.

mAbs

– – – – – – –

Bornholdt ZA et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak (2016). Science. Mar 4;351(6277):1078-83.

– – – – – – –

Testing

Walker LM et al. Broad neutralization coverage of HIV by multiple highly potent antibodies (2011). Nature. Aug 17;477(7365):466-470.

Nature

– – – – – – –

Walker LM et al. Rational antibody-based HIV-1 vaccine design: current approaches and future directions (2010). Curr Opin Immunol. Jun; 22(3):358-66.

Science Direct

– – – – – – –

Walker LM et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target (2009). Science. 326(5950):285-9.

Science

RELEVANT RESOURCES

Adagio Perspective

– – – – – – –

Adagio Therapeutics’ Tillman Gerngross on Bringing Covid-19 Antibodies to Clinical Trials

– – – – – – –

Eyeing variants, Adagio starts phase 1 trial of COVID-19 antibody

Fierce Biotech

– – – – – – –

Mutating strains and newly emerging viruses: how can one drug protect against future pandemics?

BioTechniques

– – – – – – –

GV steps up to back Tillman Gerngross’ new antibody play against Covid-19 — and he’s already thinking about the IPO

Endpoints News

– – – – – – –

Adagio Named a Winner of Fierce Biotech’s “Fierce 15 2020”

Fierce Biotech

– – – – – – –

Investors think Lebanon biotech startup may be a winner in the fight against the coronavirus

Valley News

– – – – – – –

An Audience With: Tillman Gerngross

Nature

– – – – – – –

The Case for Antibodies

– – – – – – –

Antibodies as Covid Insurance

WSJ

– – – – – – –

Monoclonal antibodies could fill the COVID-19 treatment gap until vaccines arrive — but at a cost

Seattle Times

– – – – – – –

It Will Take More Than a Vaccine to Beat COVID-19

The New Yorker

– – – – – – –

Antibody drugs could be one of the best weapons against Covid-19. But will they matter?

Stat

– – – – – – –

Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Nature

– – – – – – –

Antibody Drugs Could Help Curb the Pandemic. What Investors Need to Know.

Barron’s

– – – – – – –

Why Vaccines May Not Be Enough

– – – – – – –

Peter Marks on Covid-19 vaccine efficacy, EUAs and challenge trials

Endpoints

– – – – – – –

Coronavirus herd immunity may be ‘unachievable’ after study suggests antibodies disappear after weeks in some people

Business Insider India

– – – – – – –

Coronavirus antibodies may disappear after mere months in some people, research shows. But it’s not necessarily a reason to panic.

Yahoo!

– – – – – – –

After Trumps’ diagnosis: Vaccine or not, COVID-19 isn’t going away

USA TODAY

– – – – – – –

Nature / COVID Research Updates

Nature

INVESTORS

Board of Directors

René Russo, PharmD

Co-Founder & Chair of the Board, Adagio
Chief Executive Officer, Xilio Therapeutics

Tillman Gerngross, Ph.D.

Co-Founder & CEO of Adagio and
Adimab, LLC

Terry McGuire

Partner, Polaris Partners

Ajay Royan

Partner, Mithril Capital

Marc Elia

Founder, M28 Capital

Howard Mayer, MD

Executive Vice President, Head of Research and Development, Ipsen Pharmaceuticals